Literature DB >> 19690340

Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation.

Timothy B Campbell1, Sunanda Basu, Giao Hangoc, Wen Tao, Hal E Broxmeyer.   

Abstract

Molecular mechanisms preserving hematopoietic stem cell (HSC) self-renewal by maintaining a balance between proliferation, differentiation, and other processes are not fully understood. Hyperactivation of the mammalian target of rapamycin (mTOR) pathway, causing sustained proliferative signals, can lead to exhaustion of HSC repopulating ability. We examined the role of the novel ras gene Rheb2, an activator of the mTOR kinase, in colony-forming ability, survival, and repopulation of immature mouse hematopoietic cells. In a cell line model of mouse hematopoietic progenitor cells (HPCs), we found enhanced proliferation and mTOR signaling in cells overexpressing Rheb2. In addition, overexpression of Rheb2 enhanced colony-forming ability and survival of primary mouse bone marrow HPCs. Expansion of phenotypic HSCs in vitro was enhanced by Rheb2 overexpression. Consistent with these findings, Rheb2 overexpression transiently expanded phenotypically defined immature hematopoietic cells after in vivo transplantation; however, these Rheb2-transduced cells were significantly impaired in overall repopulation of primary and secondary congenic transplantation recipients. Our findings suggest that HPCs and HSCs behave differently in response to growth-promoting signals stimulated by Rheb2. These results may have value in elucidating mechanisms controlling the balance between proliferation and repopulating ability, a finding of importance in clinical uses of HPCs/HSCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690340      PMCID: PMC2765676          DOI: 10.1182/blood-2008-12-195214

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

2.  Hematopoietic stem cell quiescence maintained by p21cip1/waf1.

Authors:  T Cheng; N Rodrigues; H Shen; Y Yang; D Dombkowski; M Sykes; D T Scadden
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

3.  Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells.

Authors:  Hal E Broxmeyer; Lisa Kohli; Chang H Kim; Younghee Lee; Charlie Mantel; Scott Cooper; Giao Hangoc; Montaser Shaheen; Xiaxin Li; D Wade Clapp
Journal:  J Leukoc Biol       Date:  2003-05       Impact factor: 4.962

4.  SDF-1alpha/CXCL12 enhances retroviral-mediated gene transfer into immature subsets of human and murine hematopoietic progenitor cells.

Authors:  W Tao; G Hangoc; S Cooper; H E Broxmeyer
Journal:  Gene Ther       Date:  2004-01       Impact factor: 5.250

5.  A stem cell molecular signature.

Authors:  Natalia B Ivanova; John T Dimos; Christoph Schaniel; Jason A Hackney; Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

6.  The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.

Authors:  Matilde Y Follo; Sara Mongiorgi; Costanza Bosi; Alessandra Cappellini; Carlo Finelli; Francesca Chiarini; Veronica Papa; Massimo Libra; Giovanni Martinelli; Lucio Cocco; Alberto M Martelli
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

7.  Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo.

Authors:  Hal E Broxmeyer; Scott Cooper; Lisa Kohli; Giao Hangoc; Younghee Lee; Charlie Mantel; D Wade Clapp; Chang H Kim
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

Review 8.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

9.  Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.

Authors:  Magdalena Karbowniczek; Timothy Cash; Mitchell Cheung; Gavin P Robertson; Aristotelis Astrinidis; Elizabeth Petri Henske
Journal:  J Biol Chem       Date:  2004-05-18       Impact factor: 5.157

10.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

View more
  21 in total

Review 1.  Getting blood from bone: an emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche.

Authors:  Yusuke Shiozawa; Russell S Taichman
Journal:  Exp Hematol       Date:  2012-05-26       Impact factor: 3.084

2.  Cited2 is required for the maintenance of glycolytic metabolism in adult hematopoietic stem cells.

Authors:  Jinwei Du; Qiang Li; Fangqiang Tang; Michelle A Puchowitz; Hisashi Fujioka; Sally L Dunwoodie; David Danielpour; Yu-Chung Yang
Journal:  Stem Cells Dev       Date:  2013-11-12       Impact factor: 3.272

Review 3.  Insights into the biology of cord blood stem/progenitor cells.

Authors:  H E Broxmeyer
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

4.  Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice.

Authors:  Sara L Rohrabaugh; Timothy B Campbell; Giao Hangoc; Hal E Broxmeyer
Journal:  Blood Cells Mol Dis       Date:  2011-04-15       Impact factor: 3.039

5.  Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells.

Authors:  Demetrios Kalaitzidis; Dongjun Lee; Alejo Efeyan; Youmna Kfoury; Naema Nayyar; David B Sykes; Francois E Mercier; Ani Papazian; Ninib Baryawno; Gabriel D Victora; Donna Neuberg; David M Sabatini; David T Scadden
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

6.  DEPTOR is a stemness factor that regulates pluripotency of embryonic stem cells.

Authors:  Pooja Agrawal; Joseph Reynolds; Shereen Chew; Deepak A Lamba; Robert E Hughes
Journal:  J Biol Chem       Date:  2014-09-25       Impact factor: 5.157

7.  DEK regulates hematopoietic stem engraftment and progenitor cell proliferation.

Authors:  Hal E Broxmeyer; Ferdinand Kappes; Nirit Mor-Vaknin; Maureen Legendre; John Kinzfogl; Scott Cooper; Giao Hangoc; David M Markovitz
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

8.  TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1.

Authors:  Nina Chi Sabins; Olesya Chornoguz; Karen Leander; Fred Kaplan; Richard Carter; Michelle Kinder; Kurtis Bachman; Raluca Verona; Shixue Shen; Vipul Bhargava; Sandra Santulli-Marotto
Journal:  J Immunol       Date:  2017-11-10       Impact factor: 5.422

Review 9.  Recent progress in the study of the Rheb family GTPases.

Authors:  Jeffrey J Heard; Valerie Fong; S Zahra Bathaie; Fuyuhiko Tamanoi
Journal:  Cell Signal       Date:  2014-05-24       Impact factor: 4.315

Review 10.  Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function.

Authors:  Hal E Broxmeyer
Journal:  Ann N Y Acad Sci       Date:  2012-08       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.